(Q34600886)

3 August 2017

1 reference

title

Agomelatine treatment of major depressive disorder (English)

1 reference

3 August 2017

Christian R Dolder

1

1 reference

3 August 2017

Michael Nelson

series ordinal

2

1 reference

3 August 2017

Morgan Snider

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

25 November 2008

1 reference

Annals of Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

42

1 reference

3 August 2017

issue

12

1 reference

3 August 2017

page(s)

1822-1831

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

3 August 2017

cites work

1 reference

The medical management of depression

21 January 2018

1 reference

Psychosocial functioning during the treatment of major depressive disorder with fluoxetine

21 January 2018

1 reference

The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder

21 January 2018

1 reference

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

21 January 2018

1 reference

Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain

21 January 2018

1 reference

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists

21 January 2018

1 reference

Melatonin receptors and their regulation: biochemical and structural mechanisms

21 January 2018

1 reference

Melatonin receptors: molecular biology of a new family of G protein-coupled receptors

21 January 2018

1 reference

21 January 2018

1 reference

Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system

21 January 2018

1 reference

Treatment of insomnia associated with clinical depression

21 January 2018

1 reference

Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay

21 January 2018

1 reference

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas

21 January 2018

1 reference

Modulation of voltage-dependent Ca2+ conductance by changing Cl- concentration in rat lactotrophs

21 January 2018

1 reference

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor

21 January 2018

1 reference

Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

21 January 2018

1 reference

Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study

21 January 2018

1 reference

Homology modeling of MT1 and MT2 receptors

21 January 2018

1 reference

Agomelatine: a preliminary review of a new antidepressant

21 January 2018

1 reference

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats

21 January 2018

1 reference

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

21 January 2018

1 reference

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

21 January 2018

1 reference

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

21 January 2018

1 reference

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

21 January 2018

1 reference

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

Evidence of agomelatine's antidepressant efficacy: the key points

21 January 2018

1 reference

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

21 January 2018

1 reference

Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).

21 January 2018

1 reference

Agomelatine in the treatment of seasonal affective disorder

21 January 2018

1 reference

Efficacy and tolerance profile of agomelatine and practical use in depressed patients

21 January 2018

1 reference

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L296

1 reference

3 August 2017

1 reference